GlobeNewswire
-
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of March 11, 2026
12/03/2026 -
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 11 mars 2026
12/03/2026 -
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
12/03/2026 -
HealthEx Partners with Microsoft to Bring Consumers’ Personal Health History to Copilot Health
12/03/2026 -
Chemed Corporation to Present at the Oppenheimer 36th Annual Healthcare Conference
12/03/2026 -
Serotonin Centers Introduces New Medical Longevity Model for the Fitness Industry
12/03/2026 -
Cloudcure Launches Companion App to Close Clinical Adherence Gap in Metabolic Health
12/03/2026 -
Amoéba receives its first order from Koppert and confirms its transformation into a commercial company
12/03/2026 -
Curanex Expands Scientific Advisory Board With Two Distinguished Researchers
12/03/2026 -
PracticeLink Launches 2026 Webinar Series for Healthcare Recruiters
12/03/2026 -
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
12/03/2026 -
Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System
12/03/2026 -
NeurAxis to Host Fourth Quarter and Full Year 2025 Results and Business Update Call on Thursday, March 19, 2026
12/03/2026 -
Centre for Neuro Skills Appoints Curtis Shipman as Chief Information Officer
12/03/2026 -
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
12/03/2026 -
Signati™ Medical Announces Dr. LeRoy Jones Has Been Appointed as a Professor of Urology at the University of Texas San Antonio
12/03/2026 -
PROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® Therapy
12/03/2026 -
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products
12/03/2026 -
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
12/03/2026
Pages